Pro‐ and Anti‐apoptotic Members of the Bcl‐2 Family in Skeletal Muscle: A Distinct Role for Bcl‐2 in Later Stages of Myogenesis

Apoptotic myonuclei appear during myogenesis and in diseased muscles. To investigate cell death regulation in skeletal muscle, we examined how members of the Bcl‐2 family of apoptosis regulators are expressed and function in the C2C12 muscle cell line and in primary muscle cells at different stages of development. Both anti‐apoptotic (Bcl‐W, Bcl‐XL) and pro‐apoptotic (Bad, Bak, Bax) members of the Bcl‐2 family were expressed in developing skeletal muscle in vivo. Each was also expressed in embryonic (E11–12), fetal (E15–16), and neonatal muscle stem cells, myoblasts, and myotubes in vitro. In contrast, Bcl‐2 expression was limited to a small group of mononucleate, desmin‐positive, myogenin‐negative muscle cells that were seen in fetal and neonatal, but not embryonic, muscle cell cultures. The cell surface protein Sca‐1, which is associated with muscle and blood stem cells, was found on ∼1/2 of these Bcl‐2–positive cells. Loss of Bcl‐2 did not affect expression of other family members, because neonatal muscles of wild‐type and Bcl‐2–null mice had similar amounts of Bcl‐XL, Bcl‐W, Bad, Bak, and Bax mRNAs. Loss of Bcl‐2 did have functional consequences; however, because neonatal muscles of Bcl‐2–null mice had only ∼2/3 as many fast muscle fibers as muscles in wild‐type mice. Thus, Bcl‐2 function is required for particular stages of fetal and postnatal myogenesis. © 2001 Wiley‐Liss, Inc.